VNRX-5133 |
| カタログ番号GC37917 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1613268-23-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VNRX-5133 is a cyclic boronate β-lactamase inhibitor. VNRX-5133 has direct inhibitory activity against serine-active site β-lactamases (Ser-BL) and metallo-β-lactamases (MBL). VNRX-5133 is highly active against multidrug-resistant (MDR)-K. pneumonia and P. aeruginosa clinical isolates[1]. β-lactamase[1]
VNRX-5133 is a potent β-lactamase inhibitor (BLI) possessing a unique broad spectrum of activity, including Class A, C, and D Ser-BLs. VNRX-5133 enhances the activity of Cefepime against resistant Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mouse-thigh infection model[1].
[1]. Denis Daigle, PhD, et al. 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumonia and P. aeruginosa. Open Forum Infect Dis. 2018 Nov; 5(Suppl 1): S419-S420.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *